You all of course know the growth hormone PIII study ENDS on Tuesday July 12th. I suspect we will see the
data before the end of August and the filing will hopefully happen before year end. This is a slam dunk and
once approved OPK will receive $300 million cash and will immediately begin earning a royalty not only on
their drug but PFE's growth hormone drug which I believe did $900 million in 2015. PFE obviously expects to capture most of the $2 billion market with OPK'S once a week injection or they never would have paid that much for the rights to market it. Next year the company should file for the pediatric indication which could add
another $1 billion in sales. Will the multi use injector be ready by approval?
BTW, I just read a nice article on Fox Health regarding the 4K and how you can forego the biopsy.